Skip to content
  • Debatforum
  • Seneste
  • Populære
  • Bruger
Temaer
  • Light
  • Dark

Kollaps
FORSIDEN
Log ind Opret konto

Genmab — Maj 2016

Planlagt Fastgjort Låst Flyttet Genmab
2.6k Indlæg 1 Posters 0 Visninger
  • Ældste til nyeste
  • Nyeste til ældste
  • Most Votes
Svar
  • Svar som emne
Login for at svare
Denne tråd er blevet slettet. Kun brugere med emne behandlings privilegier kan se den.
  • Legolas23L Offline
    Legolas23L Offline
    Legolas23
    wrote on sidst redigeret af
    #777

    Jeg troede, vi skulle kort ned i 1009 efter åbning i 1023, men vi får se..

    1 Reply Last reply
    0
    • R Offline
      R Offline
      Repsac
      wrote on sidst redigeret af
      #778

      Det kan vi nå endnu. Kommer lidt an på hvad de anonyme beslutter sig for.

      1 Reply Last reply
      0
      • Helge_LarsenPI-redaktørH Offline
        Helge_LarsenPI-redaktørH Offline
        Helge_LarsenPI-redaktør
        wrote on sidst redigeret af
        #779

        Anonyme burde læse denne her: http://www.daytrader.dk/kobssignal-genmab-brudt-1000/?utm_source=e-mail&utm_medium=e-mail&utm_campaign=e-mail

        1 Reply Last reply
        0
        • J Offline
          J Offline
          JKY_VH
          wrote on sidst redigeret af
          #780

          Tror du de kan læse Helge?

          1 Reply Last reply
          0
          • Legolas23L Offline
            Legolas23L Offline
            Legolas23
            wrote on sidst redigeret af
            #781

            Det gapluk var da vist ramt lige i "I-love-ya"...

            1 Reply Last reply
            0
            • R Offline
              R Offline
              Repsac
              wrote on sidst redigeret af
              #782

              Ja flot.

              1 Reply Last reply
              0
              • SolsenS Offline
                SolsenS Offline
                Solsen
                wrote on sidst redigeret af
                #783

                Novartis split in two divisions - pharmaceutical og oncology.

                1 Reply Last reply
                0
                • SolsenS Offline
                  SolsenS Offline
                  Solsen
                  wrote on sidst redigeret af
                  #784

                  Viser hvor vigtig oncology er for Novartis. De har tidligere meddelt, at de overvejer at sælge deres beholdning af Roche aktier for at få cash til M&A.

                  1 Reply Last reply
                  0
                  • SolsenS Offline
                    SolsenS Offline
                    Solsen
                    wrote on sidst redigeret af
                    #785

                    De ejer ca 6% af Roche til en værdi af $14 bn. Vil herefter have ca $20 bn in cash....

                    1 Reply Last reply
                    0
                    • SolsenS Offline
                      SolsenS Offline
                      Solsen
                      wrote on sidst redigeret af
                      #786

                      Link Preview Image
                      Novartis splits drugs business into two, pharma chief to leave

                      ZURICH/LONDON (Reuters) - Novartis is splitting its pharmaceuticals division into two business units, one focused on cancer and the second on other drugs, while switching out its current pharma head in the second high-profile management reshuffle this year. David Epstein, the American head of Novartis Pharmaceuticals and a 27-year veteran with the group, will leave the company to "explore new challenges from the U.S.", Novartis said. Novartis' reorganization of its main drugs unit, which accounts for about two-thirds of its $49 billion in annual sales, shows the growing importance of oncology to the company, after it bought GSK's marketed cancer drugs for $16 billion last year.

                      favicon

                      Yahoo Finance (finance.yahoo.com)

                      1 Reply Last reply
                      0
                      • SolsenS Offline
                        SolsenS Offline
                        Solsen
                        wrote on sidst redigeret af
                        #787

                        Link Preview Image
                        Novartis May Sell Its $14 Billion Stake in Roche to Fuel Acquisitions | Fortune

                        Novartis is discussing options with banks for selling its near $14 billion stake in Roche, potentially providing cash for new deals: sources

                        favicon

                        Fortune (fortune.com)

                        1 Reply Last reply
                        0
                        • Legolas23L Offline
                          Legolas23L Offline
                          Legolas23
                          wrote on sidst redigeret af
                          #788

                          Link Preview Image
                          Gør Genmab som Novo og Coloplast?

                          Genmabs comeback på børsmarkedet har medført, at aktiekursen har rundet de magiske 1000, og det plejer normalt at afføde spekulationer om et split af aktien.

                          favicon

                          (medwatch.dk)

                          1 Reply Last reply
                          0
                          • SolsenS Offline
                            SolsenS Offline
                            Solsen
                            wrote on sidst redigeret af
                            #789

                            FDA i USA tildeler priority-review til en supplerende registreringsansøgning for ofatumumab i kombination med fludarabin og cyclofosfamid til behandling af recidiverende CLL
                            PDUFA dato sat til 10. september 2016

                            1 Reply Last reply
                            0
                            • SolsenS Offline
                              SolsenS Offline
                              Solsen
                              wrote on sidst redigeret af
                              #790

                              Det var dog vildt at de får priority-review !

                              1 Reply Last reply
                              0
                              • SolsenS Offline
                                SolsenS Offline
                                Solsen
                                wrote on sidst redigeret af
                                #791

                                Som jeg lige husker er rtx + FC golden standard

                                1 Reply Last reply
                                0
                                • M Offline
                                  M Offline
                                  Mcjean
                                  wrote on sidst redigeret af
                                  #792

                                  Alt hvad der ender på mumab får PR, det manglede bare;-)

                                  1 Reply Last reply
                                  0
                                  • Legolas23L Offline
                                    Legolas23L Offline
                                    Legolas23
                                    wrote on sidst redigeret af
                                    #793

                                    Mumbab ? Det er der skrevet en sang om https://www.youtube.com/watch?v=NHozn0YXAeE

                                    1 Reply Last reply
                                    0
                                    • F Offline
                                      F Offline
                                      forsent
                                      wrote on sidst redigeret af
                                      #794

                                      Hvad kan det potentielt betyde for salget af Arzerra? Betyder det noget sammenlignet med Dara.?

                                      1 Reply Last reply
                                      0
                                      • nohopeN Offline
                                        nohopeN Offline
                                        nohope
                                        wrote on sidst redigeret af
                                        #795

                                        priority review for ofa/fludarabin/cyclofosfamid - på hvilket grundlag ? Vellykket forsøg som jeg bare ikke har hørt om/glemt ?

                                        1 Reply Last reply
                                        0
                                        • P Offline
                                          P Offline
                                          pauly
                                          wrote on sidst redigeret af
                                          #796

                                          Dejlig nyheder, det understøtter da kursen, selv om jeg ikke kender de økonomiske konsekvenser kan det ikke være dårligt

                                          1 Reply Last reply
                                          0

                                          Hello! It looks like you're interested in this conversation, but you don't have an account yet.

                                          Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.

                                          With your input, this post could be even better 💗

                                          Tilmeld Log ind

                                          • Log ind

                                          • Har du ikke en konto? Tilmeld

                                          • Login or register to search.
                                          • First post
                                            Last post
                                          0
                                          • Debatforum
                                          • Seneste
                                          • Populære
                                          • Bruger